TCON Key Statistics, Chart & Performance
The current stock price of TCON is 1.43 USD. In the past month the price decreased by -5.3%. In the past year, price decreased by -75.43%.
TCON Technical Analysis
TCON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TCON. While TCON seems to be doing ok healthwise, there are quite some concerns on its profitability.
TCON Financial Highlights
Over the last trailing twelve months TCON reported a non-GAAP Earnings per Share(EPS) of 9.07. The EPS increased by 808.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.39% | ||
| ROA | 18.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TCON Forecast & Estimates
9 analysts have analysed TCON and the average price target is 31.11 USD. This implies a price increase of 2075.52% is expected in the next year compared to the current price of 1.43.
For the next year, analysts expect an EPS growth of -142.4% and a revenue growth -100% for TCON
TCON Ownership
TCON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.83B | ||
| AMGN | AMGEN INC | 15.48 | 182.32B | ||
| GILD | GILEAD SCIENCES INC | 17.49 | 177.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.82 | 118.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.11 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 689.8 | 46.48B | ||
| INSM | INSMED INC | N/A | 33.52B | ||
| NTRA | NATERA INC | N/A | 31.42B | ||
| BIIB | BIOGEN INC | 10.56 | 25.93B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.12 | 20.59B | ||
| INCY | INCYTE CORP | 15.72 | 19.81B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About TCON
Company Profile
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The firm offers partners a solution for the clinical development and commercialization of their products in the United States.
Company Info
TRACON PHARMACEUTICALS INC
4350 La Jolla Village Drive, Suite 800
San Diego CALIFORNIA 92122 US
CEO: Charles P. Theuer
Employees: 18
Phone: 18585500780
TRACON PHARMACEUTICALS INC / TCON FAQ
Can you describe the business of TRACON PHARMACEUTICALS INC?
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The firm offers partners a solution for the clinical development and commercialization of their products in the United States.
What is the current price of TCON stock?
The current stock price of TCON is 1.43 USD. The price decreased by -1.38% in the last trading session.
Does TRACON PHARMACEUTICALS INC pay dividends?
TCON does not pay a dividend.
What is the ChartMill rating of TRACON PHARMACEUTICALS INC stock?
TCON has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy TCON stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TCON.
Can you provide the growth outlook for TRACON PHARMACEUTICALS INC?
The Revenue of TRACON PHARMACEUTICALS INC (TCON) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for TCON stock?
TRACON PHARMACEUTICALS INC (TCON) will report earnings on 2024-08-12, after the market close.